Supplementary Material

4-Arylthiosemicarbazide derivatives as toxoplasmic aromatic amino acid hydroxylase inhibitors and anti-inflammatory agents

Adrian Bekier[1], Anna Brzostek[2], Agata Paneth[3], Bożena Dziadek[1], Jarosław Dziadek[2] , Justyna Gatkowska[1] and **Katarzyna Dzitko[1]**

[1] University of Lodz, Faculty of Biology and Environmental Protection, Department of Molecular Microbiology, Banacha 12/16, 90-237 Lodz, Poland; adrian.bekier@biol.uni.lodz.pl (A.Be.); Bożena Dziadek (B.D.) bozena.dziadek@biol.uni.lodz.pl

[2] Laboratory of Genetics and Physiology of Mycobacterium, Institute of Medical Biology, Polish Academy of Sciences, 93-232 Lodz, Poland; abrzostek@cbm.pan.pl (A.Br.); jdziadek@cbm.pan.pl (J.D.)

[3] Medical University of Lublin, Faculty of Pharmacy, Department of Organic Chemistry, Chodzki 4a, 20-093 Lublin, Poland; agatapaneth@umlub.pl (A.P.)

Table of contents:

Figure S1. SDS–PAGE of BSA from the control drug affinity responsive target stability assay.

Figure S2. Western blots of AAH1 from the drug affinity responsive target stability assay.

Table S1. The results of two-way ANOVA were conducted, and for significant comparisons, further analysis was performed using Dunnett's multiple comparisons test. The differences were considered significant with a p value < 0.05.



Figure S1. SDS–PAGE of BSA from the control drug affinity responsive target stability assay.



Figure S2. Western blots of AAH1 from the drug affinity responsive target stability assay. **A** Protection of AAH1 from proteolysis by **2a** in the presence of 10 μM of compound. **B.** Protection of AAH1 from proteolysis by **2a** in the presence of increasing concentrations of compound. **C.** Protection of AAH1 from proteolysis by **6a** in the presence of 10 μM of compound. **D.** Protection of AAH1 from proteolysis by **6a** in the presence of increasing concentrations of compound.

Table S1 The results of two-way ANOVA were conducted, and for significant comparisons, further analysis was performed using Dunnett's multiple comparisons test. The differences were considered significant with a p value < 0.05.

	NF-κB induction in THP1-Blue™			**INF-γ production**		
	Predicted mean difference	Summary	P value	Predicted mean difference	Summary	P value
TLA						
nt vs. 6a 2h a.s.	1.079	****	<0.0001	13,06	****	<0,0001
nt vs. 6a 2h b.s.	1.079	****	<0.0001	12,26	****	<0,0001
nt vs. 2a 2h a.s.	0.5013	****	<0.0001	12,50	****	<0,0001
nt vs. 2a 2h b.s.	1.076	****	<0.0001	11,86	****	<0,0001
BLA						
nt vs. 6a 2h a.s.	1.011	****	<0.0001	15,14	****	<0,0001
nt vs. 6a 2h b.s.	1.011	****	<0.0001	14,35	****	<0,0001
nt vs. 2a 2h a.s.	0.4389	****	<0.0001	14,59	****	<0,0001
nt vs. 2a 2h b.s.	1.003	****	<0.0001	14,75	****	<0,0001
AAH1						
nt vs. 6a 2h a.s.	1.657	****	<0.0001	21,04	****	<0,0001
nt vs. 6a 2h b.s.	1.914	****	<0.0001	19,92	****	<0,0001
nt vs. 2a 2h a.s.	0.8091	****	<0.0001	19,99	****	<0,0001
nt vs. 2a 2h b.s.	1.644	****	<0.0001	19,67	****	<0,0001
AAH2						
nt vs. 6a 2h a.s.	1.518	****	<0.0001	17,24	****	<0,0001
nt vs. 6a 2h b.s.	1.662	****	<0.0001	15,95	****	<0,0001
nt vs. 2a 2h a.s.	0.8798	****	<0.0001	16,92	****	<0,0001
nt vs. 2a 2h b.s.	1.466	****	<0.0001	16,20	****	<0,0001
LPS						
nt vs. 6a 2h a.s.	1.661	****	<0.0001	41,17	****	<0,0001
nt vs. 6a 2h b.s.	1.809	****	<0.0001	40,69	****	<0,0001
nt vs. 2a 2h a.s.	0.7927	****	<0.0001	40,20	****	<0,0001
nt vs. 2a 2h b.s.	1.342	****	<0.0001	40,61	****	<0,0001
not stimulated						
nt vs. 6a 2h a.s.	0.04591	ns	0.5062	-0,7622	ns	0,4697
nt vs. 6a 2h b.s.	0.04576	ns	0.5090	-1,063	ns	0,1917
nt vs. 2a 2h a.s.	0.04453	ns	0.5320	-0,4559	ns	0,8366
nt vs. 2a 2h b.s.	0.04428	ns	0.5367	-0,6224	ns	0,6416